(NASDAQ: AMRX) Amneal Pharmaceuticals's forecast annual revenue growth rate of 7.49% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.23%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Amneal Pharmaceuticals's revenue in 2026 is $3,117,548,000.On average, 10 Wall Street analysts forecast AMRX's revenue for 2026 to be $1,027,680,911,342, with the lowest AMRX revenue forecast at $974,668,160,788, and the highest AMRX revenue forecast at $1,065,684,027,703. On average, 10 Wall Street analysts forecast AMRX's revenue for 2027 to be $1,122,209,671,366, with the lowest AMRX revenue forecast at $1,049,077,623,915, and the highest AMRX revenue forecast at $1,171,070,820,973.
In 2028, AMRX is forecast to generate $1,240,689,975,315 in revenue, with the lowest revenue forecast at $1,124,125,794,880 and the highest revenue forecast at $1,371,625,082,105.